# CStone Pharmaceuticals

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/cstone-pharmaceuticals
Canonical HTML page: https://gethealthbrief.com/entity/cstone-pharmaceuticals

## Recent coverage (1 stories)

### CS2009 Trispecific Antibody Breaks 2-3 Dose Limit for CTLA-4 in ASCO 2026 Data
2026-06-15 04:21:52 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

CStone's CS2009, a first-in-class trispecific antibody, has demonstrated at ASCO 2026 that it can be dosed continuously while maintaining a safety profile similar to PD-1 monotherapy. This could transform treatment for cancer patients who previously had to stop CTLA-4 therapies early due to severe side effects.
Full story: https://gethealthbrief.com/story/cs2009-trispecific-antibody-breaks-2-3-dose-limit-asco-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.